WILMINGTON, Mass. / Feb 13, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its first Enzyme-Linked Immunosorbent Assay (ELISA) Kit for the detection and quantitation of residual host cell proteins (HCP) in CHO-based biotherapeutics. Charles River’s HCP ELISA kit achieves industry leading rates for sensitivity and specificity, reaching 0.1 ng/mL and 90 percent antibody coverage, respectively. This increase in sensitivity and specificity can be attributed to the unique chicken immunoglobulin Y (IgY) antibodies utilized.
The Benefits of IgY Antibodies
In contrast to other commercially available HCP-ELISA kits, which utilize traditional mammalian immunoglobulin G (IgG) antibodies, Charles River’s new HCP-ELISA kit leverages avian IgY antibodies as the primary detection technology. These antibodies are derived from Specific-Pathogen-Free Chicken (SPF) Eggs and developed exclusively by AVS Bio.
The main benefit of using IgY antibodies over IgG is due, in large part, to the phylogenetic differences between birds and mammals. As such, when the Avian immune system comes in contact with a mammalian antigen, it recognizes the antigen as highly foreign and processes an aggressively strong immune response compared to the conventional species (rabbits, goats) used for immunization during ELISA development.
Additional benefits are realized from the IgY antibody production process, which is non-destructive, stable from batch to batch, and provides a consistent supply of high-quality antibodies year after year.
Building Upon Established Expertise
The newly launched ELISA kit bolsters an already robust Biologics Testing offering from Charles River. The kits can be purchased individually and run by the client at their own facility, but clients are also afforded the opportunity to have Charles River’s industry experts perform the assay, providing a wide range of supporting services and decades of bench strength.
Once the drug candidate has progressed into late-phase clinical trials, Charles River’s HCP-GAPex℠ program provides a seamless transition from off the shelf generic ELISA kits to a fully validated product-specific assay, tailor-made for each product. HCP-GAPex is a holistic approach to HCP assay development which combines tools from proteomics, bioinformatics, protein synthesis, and immunology to create manufacturing processes that minimize the risk of unidentified HCP impurities, increasing efficiency and efficacy.
For more information, watch Effective HCP Control Strategies: Avoid Surprises During Late Phase Clinical Trials, a webinar presented by Olaf Stamm, PhD, Technical Business Development Director for Charles River, available on-demand.
Approved Quotes
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Last Trade: | US$178.58 |
Daily Change: | -2.81 -1.55 |
Daily Volume: | 861,401 |
Market Cap: | US$9.220B |
October 02, 2024 September 17, 2024 September 04, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB